334 related articles for article (PubMed ID: 24582506)
1. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C
Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
[No Abstract] [Full Text] [Related]
4. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
5. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
6. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
7. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
8. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
10. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Vanhaecke C; Deilhes F; Chanal J; Regnier-Rosencher E; Boitier F; Boulinguez S; Avril MF; Guégan S; Dupin N; Aractingi S; Meyer N; Kramkimel N
Br J Dermatol; 2017 Oct; 177(4):e94-e95. PubMed ID: 28129668
[No Abstract] [Full Text] [Related]
14. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
15. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
16. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
Saint-Jean M; Quéreux G; Nguyen JM; Peuvrel L; Brocard A; Vallée A; Knol AC; Khammari A; Denis MG; Dréno B
J Invest Dermatol; 2014 May; 134(5):1468-1470. PubMed ID: 24025553
[No Abstract] [Full Text] [Related]
17. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
[TBL] [Abstract][Full Text] [Related]
18. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
